昭衍新藥(06127.HK)擬8.3億元收購英茂生物科技全部股權
格隆匯4月29日丨昭衍新藥(06127.HK)發佈公吿,2022年4月28日,公司(作為買方)與英茂集團(作為賣方)訂立英茂股權轉讓協議,據此,英茂集團同意出售及公司同意購買英茂生物科技的全部股本權益,代價為人民幣8.2953億元。
根據披露,雲南英茂生物科技有限公司為一家根據中國法律合法設立並有效存續的有限公司,主營業務為實驗室實驗模型繁育和銷售。截至該公吿日期,英茂生物科技由英茂集團全資擁有。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.